

VVMF announces strategic collaboration with OXB, with view to licensing AAV and lentiviral vector platforms as first priority

Sydney, Australia, 28 October 2025

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia's first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), has commenced a strategic collaboration with OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO. Licensing of the OXB AAV and LV platforms is the first priority, with a non-binding term sheet agreed and planning for technology transfer underway.

This step marks the first phase of a broader strategic collaboration, with OXB expected to support VVMF in accelerating operational readiness (including cGMP licensing) and driving commercial success in the rapidly expanding cell and gene therapy market.

The collaboration will also seek to create future opportunities for mutual commercial benefit for both organisations and proposes that VVMF will license access to OXB's proprietary inAAVate™ and LentiVector™ platforms and associated intellectual property, enabling deployment of advanced viral vector technologies in the APAC region.



Stephen Thompson, Chief Executive Officer of VVMF, said: "We are excited to be working with OXB - a globally recognised brand in viral vector manufacturing and innovation. The strategic collaboration will help us accelerate our operational and commercial readiness and further build our presence within the global cell & gene therapy marketplace. We look forward to working closely with the OXB team as we continue to build our capabilities as Australia's first and only commercial scale GMP viral vector manufacturing facility."



Dr Sébastien Ribault, Chief Business Officer of OXB, said: "We are delighted to be working with VVMF in this exciting new chapter for cell and gene therapy in the APAC region. This is a strong endorsement of OXB's position as a global leader in viral vector development and manufacturing. By combining our proprietary platforms with VVMF's regional capabilities, we aim to accelerate VVMF's operational readiness and together expand access to advanced therapies across the region."

-ENDS-

About VVMF – Unlocking the Future of Medicine

Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia's only Contract Development and Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of viral vectors for advanced therapeutic applications. VVMF partners with researchers, clinicians, and bio-pharma companies to accelerate the path to market for cell and gene therapies to local and global patients.

Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.

Contact - For further information please contact media@vvmf.com.au

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

Enquiries:

Sebastien Ribault, Chief Business Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi